Karyopharm Therapeutics Inc.

NasdaqGS:KPTI Stock Report

Market Cap: US$89.7m

Karyopharm Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

NasdaqGS:KPTI Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 Jan 25SellUS$3,175Richard PaulsonIndividual4,055US$0.78
04 Dec 24SellUS$2,932Richard PaulsonIndividual3,620US$0.81
05 Nov 24SellUS$3,346Richard PaulsonIndividual3,675US$0.91
04 Oct 24SellUS$3,172Richard PaulsonIndividual3,607US$0.88
04 Sep 24SellUS$3,866Sohanya ChengIndividual5,356US$0.72
04 Sep 24SellUS$5,089Michael MasonIndividual7,050US$0.72
04 Sep 24SellUS$2,647Richard PaulsonIndividual3,667US$0.72
04 Sep 24SellUS$2,866Michael ManoIndividual3,971US$0.72
06 Aug 24SellUS$3,355Richard PaulsonIndividual3,608US$0.93
30 Jul 24SellUS$3,056Stuart PoultonIndividual2,883US$1.06
05 Jul 24SellUS$3,077Richard PaulsonIndividual3,616US$0.85
07 Jun 24SellUS$785,027Delphi Ventures, LLCCompany818,044US$0.98
04 Jun 24SellUS$880,693Delphi Ventures, LLCCompany906,178US$1.00
04 Jun 24SellUS$645Michael MasonIndividual652US$0.99
04 Jun 24SellUS$3,556Richard PaulsonIndividual3,592US$0.99
06 May 24SellUS$4,041Richard PaulsonIndividual3,576US$1.13
22 Apr 24SellUS$7,943Reshma RangwalaIndividual6,789US$1.17
04 Apr 24SellUS$4,596Richard PaulsonIndividual3,563US$1.29
05 Mar 24SellUS$4,645Richard PaulsonIndividual3,573US$1.30
01 Mar 24SellUS$117,399Richard PaulsonIndividual99,844US$1.20
01 Mar 24SellUS$31,684Sohanya ChengIndividual26,949US$1.20
01 Mar 24SellUS$24,150Michael ManoIndividual20,549US$1.20
01 Mar 24SellUS$26,470Stuart PoultonIndividual22,466US$1.20
01 Mar 24SellUS$25,493Reshma RangwalaIndividual21,636US$1.20
01 Mar 24SellUS$39,788Michael MasonIndividual33,849US$1.20
27 Feb 24SellUS$3,369Michael MasonIndividual2,545US$1.32
15 Feb 24SellUS$7,783Stuart PoultonIndividual5,847US$1.40
06 Feb 24SellUS$6,671Michael MasonIndividual4,205US$1.59
06 Feb 24SellUS$6,365Richard PaulsonIndividual4,012US$1.59

Insider Trading Volume

Insider Buying: KPTI insiders have only sold shares in the past 3 months.


Ownership Breakdown

What is the ownership structure of KPTI?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders772,2310.616%
Hedge Funds9,744,8857.78%
General Public45,704,04536.5%
Institutions69,093,34555.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.4%.


Top Shareholders

Top 25 shareholders own 57.3% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
7.78%
Highbridge Capital Management, LLC
9,744,885US$7.0m0%0.16%
6.11%
The Vanguard Group, Inc.
7,654,482US$5.5m0%no data
5.48%
J. Wood Capital Advisors LLC
6,872,027US$4.9m0%no data
4.43%
Eversept Partners, L.P.
5,547,880US$4.0m11.2%0.32%
4.07%
Palo Alto Investors LP
5,102,193US$3.7m0%0.52%
3.78%
Avidity Partners Management, L.P.
4,741,060US$3.4m135%0.19%
3.45%
Adage Capital Management, L.P.
4,319,842US$3.1m0%0.01%
2.9%
BlackRock, Inc.
3,638,378US$2.6m-12.7%no data
2.48%
Citadel Advisors LLC
3,103,669US$2.2m0.07%no data
1.66%
Marshall Wace LLP
2,082,226US$1.5m-19.3%no data
1.58%
BNP Paribas Arbitrage Sa, Asset Management Arm
1,982,354US$1.4m-12.8%no data
1.42%
GSA Capital Partners LLP
1,775,700US$1.3m80.6%0.1%
1.2%
C WorldWide Asset Management Fondsmaeglerselskab A/S
1,500,000US$1.1m0%0.01%
1.11%
JPMorgan Chase & Co, Brokerage and Securities Investments
1,385,724US$992.2k8.61%no data
1.08%
Geode Capital Management, LLC
1,355,392US$970.5k3.34%no data
1.07%
Goldman Sachs Group, Investment Banking and Securities Investments
1,336,715US$957.1k-39.4%no data
1.01%
Deutsche Asset & Wealth Management
1,268,777US$908.4k0%no data
1%
Millennium Management LLC
1,255,264US$898.8k-40%no data
0.99%
Renaissance Technologies LLC
1,241,407US$888.8k64.2%no data
0.96%
Kennedy Capital Management LLC
1,204,009US$862.1k0.6%0.02%
0.95%
UBS O'Connor LLC
1,196,174US$856.5k8.51%0.08%
0.9%
Alphacentric Advisors LLC
1,125,000US$805.5k0%0.58%
0.84%
D. E. Shaw & Co., L.P.
1,047,396US$749.9k24.1%no data
0.59%
Altium Capital Management LP
740,000US$529.8k0%0.17%
0.46%
Point72 Asset Management, L.P.
578,682US$414.3k-24.9%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 01:38
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Karyopharm Therapeutics Inc. is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Peter LawsonBarclays
Ying HuangBofA Global Research